$386.37 Million in Sales Expected for Qiagen NV (NYSE:QGEN) This Quarter

Equities analysts forecast that Qiagen NV (NYSE:QGEN) will announce $386.37 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Qiagen’s earnings. The highest sales estimate is $395.00 million and the lowest is $381.36 million. Qiagen posted sales of $377.20 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 2.4%. The business is scheduled to announce its next quarterly earnings report after the market closes on Tuesday, July 30th.

According to Zacks, analysts expect that Qiagen will report full-year sales of $1.57 billion for the current fiscal year, with estimates ranging from $1.57 billion to $1.58 billion. For the next financial year, analysts anticipate that the company will post sales of $1.72 billion. Zacks’ sales averages are a mean average based on a survey of analysts that cover Qiagen.

Qiagen (NYSE:QGEN) last announced its earnings results on Monday, May 6th. The company reported $0.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.26 by $0.01. Qiagen had a return on equity of 12.22% and a net margin of 12.45%. The firm had revenue of $348.70 million for the quarter, compared to analyst estimates of $351.68 million. During the same quarter last year, the firm posted $0.26 EPS. The business’s revenue was up 1.5% on a year-over-year basis.

A number of research analysts have weighed in on the company. Deutsche Bank lowered Ontex Group from a “buy” rating to a “hold” rating in a report on Wednesday, May 8th. Exane BNP Paribas upgraded Qiagen from a “neutral” rating to an “outperform” rating in a report on Friday, July 12th. BNP Paribas upgraded Qiagen from a “neutral” rating to an “outperform” rating in a report on Friday, July 12th. Barclays raised their price objective on from GBX 200 ($2.61) to GBX 210 ($2.74) and gave the company an “equal weight” rating in a report on Friday, June 21st. Finally, Goldman Sachs Group lowered JSR from a “neutral” rating to a “sell” rating in a report on Friday, June 21st. Five investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $42.00.

Institutional investors and hedge funds have recently modified their holdings of the business. Campbell & CO Investment Adviser LLC acquired a new stake in shares of Qiagen in the 1st quarter worth $229,000. PNC Financial Services Group Inc. increased its stake in shares of Qiagen by 1.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 205,337 shares of the company’s stock worth $8,353,000 after acquiring an additional 3,609 shares during the last quarter. Cornerstone Advisors Inc. acquired a new stake in shares of Qiagen in the 1st quarter worth $44,000. D. E. Shaw & Co. Inc. increased its stake in shares of Qiagen by 19.8% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,756,276 shares of the company’s stock worth $60,489,000 after acquiring an additional 290,673 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Qiagen by 8.9% in the 4th quarter. Geode Capital Management LLC now owns 584,780 shares of the company’s stock worth $20,145,000 after acquiring an additional 47,932 shares during the last quarter. 63.20% of the stock is owned by institutional investors and hedge funds.

QGEN stock traded up $0.08 during midday trading on Friday, reaching $39.58. The stock had a trading volume of 354,400 shares, compared to its average volume of 1,206,018. The firm has a fifty day moving average price of $39.67. The company has a current ratio of 1.69, a quick ratio of 1.52 and a debt-to-equity ratio of 0.54. The stock has a market cap of $8.91 billion, a P/E ratio of 29.54, a price-to-earnings-growth ratio of 2.46 and a beta of 0.84. Qiagen has a 52-week low of $32.33 and a 52-week high of $41.55.

About Qiagen

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.

Further Reading: Why is the ROA ratio important?

Get a free copy of the Zacks research report on Qiagen (QGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.